The Research Is Moving.
The Details Matter.

Personalized neoantigen vaccines are being studied in several cancer settings, with the strongest public evidence still limited to specific populations and trial phases.

ImmunaPath exists to make the evidence, limitations, trial information, expanded-access rules, and current published cost models easier to understand.

Why the Gap Exists

visibility_off

Patients Don't Know

Trial records, journal articles, FDA guidance, and sponsor information are difficult to read together. Expanded access may be a route in some cases, but it is not guaranteed and requires agreement from multiple clinical and regulatory parties.

account_tree

The Process Is Complex

A case may involve a treating physician, sponsor or manufacturer, an institutional review board, the FDA, sequencing, manufacturing, informed consent, timing, and cost. The exact pathway depends on the trial or expanded-access program.

payments

Cost Is a Barrier

JLF currently publishes a model of roughly $92,000 before treating-physician administration, which it lists separately at approximately $7,000–$25,000. Other programs and coverage decisions can differ and must be checked directly.

What ImmunaPath Does

ImmunaPath is an independent research and education resource for patients and families exploring personalized cancer vaccines. We provide:

school

Plain-Language Research Updates

Careful updates translating clinical trial results, FDA information, and scientific developments into language patients and families can understand.

checklist

Educational Tools

A non-scoring oncology conversation checklist and an adjustable cost-model explorer. Neither determines medical eligibility, treatment, coverage, or a price quote.

menu_book

Comprehensive Guides

In-depth explanations of FDA expanded access, the treatment process, costs, legal frameworks, and what questions to ask your oncologist.

What We Are Not

Transparency matters, especially in healthcare. Here's what ImmunaPath is not:

  • × Not a medical provider. We do not diagnose, prescribe, or treat. All medical decisions are between you and your physician.
  • × Not a substitute for your oncologist. Our tools provide general guidance. Your doctor has your complete medical picture.
  • × Not making promises. Personalized cancer vaccines are an emerging field. Results vary. Not every patient is a candidate, and not every treatment succeeds.
  • × Not selling treatment. We don't manufacture vaccines, sell medical products, or profit from your treatment decisions.

Evidence Snapshot

Phase 2b

Peer-reviewed melanoma evidence

Phase 3

Confirmation study underway

Investigational

Not generally approved treatment

Specific

Evidence depends on product and setting

Start Here

Start with the evidence, then bring the relevant questions to your oncology team.

Questions for Your Oncologist Estimate Costs Subscribe